title: Use of DMPC and DSPC lipids for verapamil and naproxen permeability studies by PAMPA.
abstract: Verapamil and naproxen Parallel Artificial Membrane Permeability Assay (PAMPA) permeability was studied using lipids not yet reported for this model in order to facilitate the quantification of drug permeability. These lipids are 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and an equimolar mixture of DMPC/DSPC, both in the absence and in the presence of 33.3 mol% of cholesterol. PAMPA drug permeability using the lipids mentioned above was compared with lecithin-PC. The results show that verapamil permeability depends on the kind of lipid used, in the order DMPC > DMPC/DSPC > DSPC. The permeability of the drugs was between 1.3 and 3.5-times larger than those obtained in lecithin-PC for all the concentrations of the drug used. Naproxen shows similar permeability than verapamil; however, the permeability increased with respect to lecithin-PC only when DMPC and DMPC/DSPC were used. This behavior could be explained by a difference between the drug net charge at pH 7.4. On the other hand, in the presence of cholesterol, verapamil permeability increases in all lipid systems; however, the relative verapamil permeability respect to lecithin-PC did not show any significant increase. This result is likely due to the promoting effect of cholesterol, which is not able to compensate for the large increase in verapamil permeability observed in lecithin-PC. With respect to naproxen, its permeability value and relative permeability respect lecithin-PC not always increased in the presence of cholesterol. This result is probably attributed to the negative charge of naproxen rather than its molecular weight. The lipid systems studied have an advantage in drug permeability quantification, which is mainly related to the charge of the molecule and not to its molecular weight or to cholesterol used as an absorption promoter.
authors.affiliation: Departamento de Farmacia and.
authors.forename: M J
authors.initials: MJ
authors.lastname: Alvarez-Figueroa
authors.forename: B C
authors.initials: BC
authors.lastname: Contreras-Garrido
authors.forename: M A
authors.initials: MA
authors.lastname: Soto-Arriaza
mesh_terms: D065567:Absorption, Physiological; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000032:analysis / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000032:analysis / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D002463:Cell Membrane Permeability / Q000187:drug effects; D002784:Cholesterol / Q000737:chemistry; D004134:Dimyristoylphosphatidylcholine / Q000737:chemistry; D006801:Humans; D007700:Kinetics; D054709:Lecithins / Q000737:chemistry; D008567:Membranes, Artificial; D008954:Models, Biological; D009288:Naproxen / Q000032:analysis / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D010539:Permeability; D010713:Phosphatidylcholines / Q000737:chemistry*; D014700:Verapamil / Q000032:analysis / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002121:Calcium Channel Blockers; D054709:Lecithins; D008567:Membranes, Artificial; D010713:Phosphatidylcholines; D009288:Naproxen; D002784:Cholesterol; D014700:Verapamil; C010942:1,2-distearoyllecithin; D004134:Dimyristoylphosphatidylcholine
keywords: DMPC; DSPC; PAMPA; naproxen; verapamil